Mar 15, 2019
Adlai Nortye's Buparlisib (AN2025) Set to Become a Potential Treatment for Anti-PD-1 Non-responding Tumor in HNSCC
Mar 12, 2019
Hematogenix Launches FDA Approved Companion Diagnostic Immuno-oncology Test for Triple-Negative Breast Cancer
Feb 19, 2019
Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody
Jan 22, 2019
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy
Jan 13, 2019
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
Jan 07, 2019
Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2
Nov 18, 2018
CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China
Nov 13, 2018
A new PD-L1 BOND Ready-to-Use antibody, providing you with the freedom and flexibility to develop the tests you need
Nov 06, 2018
Tocagen to Present Updated Data from Clinical and Preclinical Studies at Three Scientific and Medical Conferences
Oct 30, 2018
Sirona Dx Launches Novel Urine-Based Bladder Cancer Assay with PD-L1 Quantification Based on IncellDx's Single Cell Immuno-Oncology/PD-L1 Technology
Oct 23, 2018
CStone Receives US FDA IND Approval for Recombinant PD-1 mAb CS1003
Oct 23, 2018
KN035, a Global Leading Subcutaneously-administered PD-L1 Antibody, Starts Late-stage Clinical Development
Oct 22, 2018
Merck KGaA, Darmstadt, Germany, Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress
Oct 10, 2018
Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial
Oct 10, 2018
Immune Checkpoint Inhibitors Market is Anticipated to Cross US$ 25 Billion by 2022 Due to Increasing Prevalence of Cancer and Immune Diseases: Radiant Insights, Inc.
Sep 10, 2018
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
Aug 28, 2018
Global PD-1 and PD-L1 Inhibitors Market 2018-2022: PD-1 and PD-L1 Inhibitors Market by Value, Treatment and Cancer Type - Focus on China, US & Globe
Aug 27, 2018
CStone's Anti-CTLA-4 Antibody CS1002 Receives IND Approval in China
Aug 21, 2018
IncellDx Launches BioINK PD-L1 CTC Core Kit with Lyophilized CTC Control Cells for Microfluidic Liquid Biopsies
Aug 15, 2018
Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022